Skip to content

XOMA Royalty has been acquired by Ligand.

Please visit ligand.com for more information.

About Us
Royalty Portfolio
Opportunities
News
- Company & Portfolio News
- Press Releases
Investors
Acquisitions
Contact

About Us
Royalty Portfolio
Opportunities
News
- Company & Portfolio News
- Press Releases
Investors
Acquisitions
Contact

Clinical Trials

D-Fi (FCX-007)

Evaluation of D-Fi for the Treatment of Wounds Due to DEB
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terms of Use

Terms of Use

© 2026 XOMA Royalty Corporation. All rights reserved.

Follow us:

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.